Sort   by:  
 Page size 
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42019 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgM 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42020 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42145 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:200]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42150 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgG 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42163 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:200]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42179 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgM 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42175 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42176 | biostudies-arrayexpress
TranscriptomicsDysregulated expression of genes in regulatory T cells from metastatic castration-resistant prostate cancer patients
We analyzed the global gene expression pattern of Tregs between healthy donors and prostate cancer patients. We found that genes related to cell cycle, cellular proliferation, immune responses, hematological system development and function were differentially expressed in Tregs from prostate cancer...
ORGANISM(S): Homo sapiens 
2013-03-05 | E-GEOD-38043 | biostudies-arrayexpress
UnknownCirculating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Not available
S-EPMC7925349 | biostudies-literature
Sort   by:  
 Page size